THIS WEBINAR ENDED. YOU CAN ACCESS THE RECORDING BELOW.
Wednesday, June 20, 2018
GMT: 15:00 | CET: 16:00
EST: 10:00 | PST: 7:00 | IST: 20:30
Please join rfxcel for a webinar presentation regarding Data Integrity in the Pharmaceutical Supply Chain. During this 45 minute webinar, we will cover the areas of :
1. Why data integrity is only as good as the weakest link
2. How data errors can occur in validated systems
3. Why active error checking is needed.
4. What regulators are planning
5. How you can prepare
This webinar will be hosted by Mark Davison, Senior Operations Director in Europe, at rfxcel. Mark is a leading traceability and digital health expert as well as the published author of “Pharmaceutical Anti-Counterfeiting: Combating the Real Danger from Fake Drugs.” Mark specializes in global health and big data issues such as serialization, supply chain security, patient safety and government policy.
Please note that this webinar will be recorded, and a copy of this session will be sent to all attendees. If you are unable to attend this webinar but would like to receive a copy following, please register below and we will oblige accordingly.
rfxcel is the leading provider of SaaS-based track and trace solutions. The platform enables companies to protect patients, comply with regulatory mandates, and gain visibility into their supply chain. rfxcel’s relentless commitment to customer success and continuous innovation ensures that companies can meet today’s requirements and tomorrow’s challenges.
PLEASE FILL OUT FORM TO ACCESS WEBINAR RECORDING:
San Ramon, CA May 23, 2018 – rfxcel Corporation, a technically certified Gateway Provider for the European Medicines Verification Organisation (EMVO) announced today that it will pay the cost of statutory fees payable to EMVO* for all manufacturers (Marketing Authorisation Holders, MAHs) which select rfxcel as their Gateway Provider before June 15th 2018.
Manufacturers who wish to participate in this great opportunity should contact rfxcel (email@example.com) for details of the solution and terms of the offer. They then simply need to name rfxcel as their Gateway Provider when registering on the EMVO portal (https://emvo-medicines.eu/pharmaceutical-companies) before June 15th 2018. When we conclude a software contract, the cost of the EMVO fee will be absorbed by rfxcel as a discount.
With EMVO onboarding fees increasing by 50% after June 15th 2018, rfxcel is taking a significant step in helping EMVO to accelerate its onboarding programme and MAHs to meet their requirements under the Falsified Medicines Directive in a timely manner.
rfxcel provides a full-service, fixed price approach that gets MAHs ready to exchange data with EMVO quickly and efficiently. We manage the end to end process from EMVO onboarding to connection, reporting and interaction with business partners such as contract manufacturers (CMOs). This enables even very small MAH companies to comply with FMD obligations with minimum resource and cost impact.
“Our initiative to cover the cost of the EMVO onboarding fee, paired with our rapid, full-service implementation, provides a great opportunity to MAHs who need move quickly. With rfxcel they also avoid the hidden costs and additional resources required by other solution providers to onboard their trading partners”, said Mark Davison, rfxcel Senior Director of Operations Europe.
To learn more about the requirements surrounding the European Union’s Falsified Medicines Directive (FMD) or rfxcel’s solutions to meet these needs, please contact us.
*The offer relates to EMVO (one-time) onboarding fees only. It does not include any initial or annual fees that may be payable to national medicine verification organisations (NMVOs).
For more information contact us:
Herb Wong, VP Marketing